[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100534911":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":33,"responsibleParty":49,"collaborators":19,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":19,"enrollmentInfo":60,"targetDuration":19,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":19,"overallStatus":36,"whyStopped":19,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Radboud University Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention","EXPERIMENTAL","Patients will undergo a PET\u002FCT scan at t=60 min after a single intravenous injection of a fixed dose of 100 MBq +\u002F- 10% \\[68Ga\\]Ga-DFO-B (gallium-68-deferoxamine) which contains 100 µg deferoxamine (DFO-B).",[13],"Other: Radiopharmaceutical: gallium-68-deferoxamine ([68Ga]Ga-DFO-B)",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Radiopharmaceutical: gallium-68-deferoxamine ([68Ga]Ga-DFO-B)","100 MBq +\u002F- 10% \\[68Ga\\]Ga-DFO-B which contains 100 µg DFO-B (see description in arm description)",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Roger Brüggemann, PhD","PRINCIPAL_INVESTIGATOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Laura Michon","CONTACT","024 361 1111","laura.michon@radboudumc.nl",{"name":31,"role":27,"phone":28,"phoneExt":19,"email":32},"Roger Brüggemann","roger.bruggemann@radboudumc.nl",[34],{"facility":35,"status":36,"city":37,"state":19,"zip":19,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"RadboudUMC","RECRUITING","Nijmegen","Netherlands","NL",{"type":41,"coordinates":42},"Point",[43,44],5.85278,51.8425,{"lat":44,"lon":43},[47],{"name":48,"role":27,"phone":28,"phoneExt":19,"email":29},"Laura Michon, MSc",{"type":50,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100534911","phase-2-imaging-pulmonary-aspergillosis-using-gallium-68-deferoxamine-100534911",false,"NCT06244979","iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine","MIRAGE","Inclusion Criteria:\n\n1. The patient is at least 18 years old on the day of inclusion.\n2. The patient has suspected chronic pulmonary aspergillosis or ABPA.\n3. There is no significant interference with standard care and follow-up.\n\nExclusion Criteria:\n\n1. The patient is pregnant or planning on becoming pregnant.\n2. The patient has severe kidney dysfunction with eGFR \\\u003C 30 ml\u002Fmin\u002Fkg and\u002For receives dialysis.\n3. The patient has (chronic) iron overload.\n4. The patient has been receiving antifungal treatment for more than 48 hours prior to the study day.\n5. The patient is not able to lie still in the scanner.","ALL","18 Years",{"count":61,"type":62},10,"ESTIMATED","INTERVENTIONAL",[65],"PHASE2","This is a single center open-label feasibility trial involving a single study visit for participants. The purpose of the study is to demonstrate the feasibility of \\[68Ga\\]Ga-DFO-B PET\u002FCT (gallium-68-deferoxamine) for the visualization of pulmonary Aspergillus infection.\n\nThe incidence of fungal infections is on the rise and are associated with significant mortality. Diagnosis pulmonary aspergillosis can be can be challenging, often requiring invasive tests such as bronchoscopy and lung tissue biopsies. Molecular imaging, specifically using radiolabeled siderophores like \\[68Ga\\]Ga-DFO-B, offers a non-invasive and location-specific approach to visualize and evaluate infections. Siderophores, critical for pathogenic microbes like Aspergillus fumigatus, play a role in iron acquisition. Preclinical studies with radiolabeled deferoxamine (DFO-B) demonstrated distinct accumulation at infection sites. Additionally, \\[68Ga\\]Ga-DFO-B PET\u002FCT may differentiate between Aspergillus infection and cancer, making it a promising non-invasive diagnostic tool for pulmonary aspergillosis.",[68,69,70],"Pulmonary Aspergillosis","Chronic Pulmonary Aspergillosis","Allergic Bronchopulmonary Aspergillosis","2025-05-19",{"date":73,"type":74},"2025-05-22","ACTUAL",{"date":76,"type":74},"2025-05-01",{"date":78,"type":62},"2026-05-01",{"name":5,"class":6},1]